AVRO News and Press, AVROBIO Inc. From 02/25/21

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in three upcoming virtual investor conferences. ...

AVRO dropped after bluebird's lentiglobin trials were halted because of AML/MDS concerns. Both therapies use Lentiviral vectors, hence the concern. However, Kymriah also uses Lentiviral vectors, and there have been no reports of secondary malignancies. For further details se...

Gainers: Luokung Technology (LKCO) +112%.Kubient (KBNT) +63%.SOS (SOS) +58%.Torchlight Energy Resources (TRCH) +54%.Protective Insurance (PTVCB) +53%.500.com (WBAI) +45%.ALJ Regional (ALJJ) +45%.Urban Tea (MYT) +44%.Canaan (CAN) +36%.Applied Genetic Technologies (AGTC) +32...

Before the open, bluebird bio ([[BLUE]] -33.6%) announced it was suspending two Phase 1/2 clinical trials for the gene therapy candidate, LentiGlobin in sickle cell disease (“SCD”)The investigations were ongoing to determine if there was a relationship to the use of BB305 lentiv...

The following slide deck was published by AVROBIO, Inc. in conjunction with this event. For further details see: AVROBIO (AVRO) Presents At 17th Annual Virtual WORLDSymposium 2021 - Slideshow

Avrobio (AVRO) jumps 20% premarket following an announcement of 100% reduction, or complete clearance, of toxic substrate in the kidney biopsy of the first patient dosed with the plato gene therapy platform in Phase 2 FAB-GT clinical trial of AVR-RD-01, an investigati...

Consistent with the 87% reduction in the first evaluable kidney biopsy, there is complete clearance of Gb3 inclusions in second evaluable kidney biopsy in Fabry disease Phase 2 trial New Gaucher disease type 1 Phase 1/2 data show plasma chitotriosidase levels decreased 49% and...

Analyst and investor event scheduled for Monday, Feb. 8 at 8:00 a.m. ET Four platform presentations and two posters on the company’s clinical and preclinical programs for lysosomal disorders are scheduled throughout 17 th annual WORLDSymposium™ AV...

AVROBIO, Inc. (Nasdaq:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced Azadeh Golipour, VP of Manufacturing Operations at AVROBIO, will present virtually at the Cowen 2021 Gene Therapy: CMC & R...

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced the appointment of Diana M. Escolar, M.D., FAAN, as chief medical officer. Dr. Escolar brings deep expertise across rare dise...